Genfleet Therapeutics Rises on KRAS Inhibitor Progress & Investor Confidence
Genfleet Therapeutics shows modest gains as its KRAS inhibitor fulzerasib advances with Innovent, positioning the company for future oncology growth.
- GENFLEET THERAPEUTICS SHAN-H
- China
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read